Scarica l'app Stockscreener
5.94
3.26%
-0.20
Serina Therapeutics Inc Borsa (SER) Ultime notizie
Juvenescence Lands $76M Funding and M42 Partnership to Transform Drug Development in Abu Dhabi - Stock Titan
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 - GlobeNewswire Inc.
VivaTech 2025: A record-setting edition with 180,000 visitors - The Globe and Mail
Serina Therapeutics Congratulates Juvenescence on Securing $150 Million Series B Financing and Strategic Alliance with M42 - Nasdaq
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 - GlobeNewswire
$150M Biotech Deal: Juvenescence Partners With M42 to Launch AI-Powered Drug Hub in Abu Dhabi - Stock Titan
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" - StreetInsider
Registration Is Now Open For Tribe Public’s CEO - GlobeNewswire
Biotech Bear Market Creates Massive Opportunity: 25% of US Firms Trading Below Enterprise Value - Stock Titan
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients - The Globe and Mail
Nvidia's Big Moment Is Just Ahead. Here's What to Watch For. - The Globe and Mail
Serina Therapeutics Appoints Dr. Stephen Brannan to Board of Directors to Enhance CNS Therapeutic Development - Nasdaq
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors - The Manila Times
Karuna's $14B Exit Architect Joins Serina Board: CNS Drug Development Expert to Guide Neural Pipeline - Stock Titan
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan - GlobeNewswire
Parkinson's Drug Developer Serina Therapeutics Expands Team with Equity Incentives Worth 15,000 Shares - Stock Titan
JonesTrading Keeps Their Buy Rating on Serina Therapeutics (SER) - The Globe and Mail
Serina Therapeutics Advances SER-252 for Parkinson’s Disease and Strengthens Leadership and Financial Position - Nasdaq
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail
Serina Therapeutics to Present at JonesResearch Virtual CNS Day - The Manila Times
Serina Therapeutics CEO to Showcase Revolutionary CNS Drug Technology: Key Presentation Details Revealed - Stock Titan
Serina Therapeutics Says May Offer And Sell Shares Of Common Stock Of Up To $13.3 Million - marketscreener.com
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit - GlobeNewswire
Revolutionary Drug Delivery Tech Could Make mRNA Vaccines Safer: New Trial Data - Stock Titan
Serina Therapeutics closes $5 million funding for Parkinson’s trial By Investing.com - Investing.com Canada
Serina Therapeutics Secures $5 Million Funding - MarketScreener
Serina Therapeutics closes $5 million funding for Parkinson’s trial - Investing.com
Serina Therapeutics Secures $5 Million in Funding to - GlobeNewswire
Revolutionary Parkinson's Treatment Gets $5M Boost: Serina's New Drug Heads to Clinical Trials - Stock Titan
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Serina's Game-Changing POZ Platform Takes Center Stage at Major Healthcare Conference - Stock Titan
Serina Therapeutics Files For Mixed Shelf Of Upto $100 MillionSEC Filing - MarketScreener
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Serina Therapeutics to Present Novel Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring 2025 Meeting - Nasdaq
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting - GlobeNewswire
Jones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy Recommendation - Nasdaq
Serina Therapeutics initiated with a Buy at JonesResearch - TipRanks
Serina Therapeutics Appoints Dr. Venkatesan to Board - TipRanks
Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire
Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - MSN
Serina secures additional $5 million for Parkinson's trial - MSN
Earnings To Watch: e.l.f. Beauty (ELF) Reports Q4 Results Tomorrow - The Globe and Mail
Serina secures additional $5 million for Parkinson's trial By Investing.com - Investing.com Australia
Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics - MarketWatch
Serina Therapeutics's Shares Up Following $5M of Equity Financing - MarketWatch
Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position - Marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Serina Therapeutics receives funding to advance SER-252 into clinical trial - TipRanks
0.68%
0.50%
Capitalizzazione:
|
Volume (24 ore):